Goldenwell Biotech, Inc. (GWLL)

A. Company Overview

Goldenwell Biotech, Inc. is a biotechnology company that was incorporated on August 20, 2019. The company is located at 581 Boston Mills Road, Suite 300, Hudson, Ohio 44236. It serves primarily as an administrative office, handling mail and logistics rather than conducting active operations. The company's fiscal year concludes on December 31.

B. Corporate History and Background

As a relatively new entity within the biotechnology sector, Goldenwell Biotech focuses on the research and development of specialized products derived from biopharmaceuticals. The company was founded with the intent to innovate and introduce unique health solutions to the market. With no subsidiaries, its corporate structure remains streamlined, focusing its efforts on its core offerings.

C. Intellectual Property and Licensing Agreements

Goldenwell Biotech has established significant intellectual property through exclusive license agreements with two entities.

1. Australian Trefoil Health Technologies Pty Ltd: As of July 20, 2020, the company entered into an Exclusive License Agreement with this Australian firm. This agreement allows Goldenwell to utilize the technologies and packaging designs related to its Sugar Master and DNA Repair products, among others. The licensing rights extend globally, excluding China, and are effective until November 15, 2025. A nominal fee of $10.00 was paid to secure this agreement.
2. Ji Lin JZY Biotech Inc.: In conjunction with the Australian license, Goldenwell also executed a similar agreement with Ji Lin JZY Biotech, effective on the same date. This agreement permits the use of proprietary technologies essential to Goldenwell's product line. The terms mirror those of the Australian agreement, lasting until January 11, 2035, with a $10.00 fee for entry.

Both licensing agreements are crucial to Goldenwell’s operation as they provide access to innovative technologies vital for product development.

D. Product Portfolio

Goldenwell Biotech has developed a product line that is categorized into polypeptide freeze-dried powders and solid tablet formulations. These products focus on health and wellness, targeting various physiological needs.

Category I: Polypeptide Freeze-Dried Powders

1. JI MAI – Bovine Cardiac Vascular Active Peptide:

- This product is derived from bovine cardiac vascular tissues processed under controlled low-temperature conditions. The peptide is designed to provide various bioactive substances that may aid in vascular health.

1. Double Proline AG – 3D Active Collagen Peptide (DPAG):

- Targeted as a drinkable cosmetic, this product is crafted from bovine or ox tendon, processed similarly as the JI MAI product. It focuses on promoting skin elasticity and overall structural integrity in bodily tissues.

1. Cartilage Peptide – Type II Collagen Peptide:

- Extracted from bovine or pig cartilage, this product functions as a dietary supplement composed primarily of collagen peptides. The benefits purportedly include support for joint health and increased calcium supplementation.

Category II: Solid Tablets

1. Se Plus:

- This tablet utilizes L-Se-Methylselenocysteine, recognized for its antioxidant properties, with a focus on enhancing overall health and supporting physiological functions.

1. Sugar Master:

- Leveraging low-temperature extraction techniques, this product aims to maximize bioactive components from plant matter, particularly targeting metabolic health and dietary supplementation.

E. Status of Production

Goldenwell Biotech has completed initial stages for its product offerings, including site location and equipment setup. The necessary manufacturing equipment is readily available, and future production will require standard workforce training, which does not necessitate specialized skills.

F. Competitive Environment

The competitive landscape for Goldenwell Biotech includes traditional offline consumer resources as well as online providers of health and wellness products. The company strives to differentiate itself based on the breadth of its service offerings, reliability of product information, and the recognition of its brand in the marketplace.

G. Regulatory Environment

As of now, Goldenwell Biotech does not face any explicit governmental regulations or approvals that would impede its operations or product offerings. Moreover, there is no indication that the company is subjected to restrictions relating to intellectual property ownership and licensing.

H. Facilities and Management

Goldenwell's physical presence is limited to its office in Hudson, OH, with no additional real estate holdings or significant physical properties. The company is operated by three non-employee officers, indicating a lean management structure driving its operations.